




>>Entry Name: Bexarotene, USAN

Synonym(s): 4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid, 9Cl. Targretin. Targrexin. LGD 1069



CAS Registry Number: 153559-49-0

Related CAS Registry Numbers(s): 160436-02-2

Molecular Formula: C₂₄H₂₈O₂

Molecular Weight: 348.484

Accurate Mass: 348.20893

Percentage Composition: C 82.72%; H 8.10%; O 9.18%

Biological Use/Importance: Retinoid X receptor (RXR) selective ligand (a rexinoid). Inhibits tumour cell proliferation. Used in the treatment of cutaneous T-cell lymphoma. Antidiabetic agent

Physical Description: Cryst. (EtOAc/hexane)

Development Status: Approved by FDA (1999)

Melting Point: Mp 234°

UV: [neutral] λ_{max} 264 (ε 16400) (MeOH)

>>Derivative: Me ester

CAS Registry Number: 153559-48-9

Molecular Formula: C₂₅H₃₀O₂

Molecular Weight: 362.511

Accurate Mass: 362.22458

Percentage Composition: C 82.83%; H 8.34%; O 8.83%

Physical Description: Powder

Melting Point: Mp 160-161°

References:

Pat. Coop. Treaty (WIPO), 1993, *Ligand Pharmaceuticals*, 93 21 146; CA, **120**, 217004k, (synth, pharmacol)

Boehm, M.F. *et al.*, *J. Med. Chem.*, 1994, **37**, 2930-2941, (synth, pmr, uv, pharmacol)

Nadzan, A.M. *et al.*, *Eur. J. Med. Chem. (Chim. Ther.)*, 1995, **30**, 519s-533s, (rev)

Gottardis, M.M. *et al.*, *Cancer Res.*, 1996, **56**, 5566-5570, (pharmacol)

Miller, V.A. *et al.*, *J. Clin. Oncol.*, 1997, **15**, 790-795, (clin trial)